Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123,180,519
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
33,946,250
-
Shares change
-
+8,695,965
-
Total reported value, excl. options
-
$93,689,694
-
Value change
-
+$24,746,037
-
Put/Call ratio
-
8.82%
-
Number of buys
-
43
-
Number of sells
-
-18
-
Price
-
$2.76
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q2 2017
79 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2017.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33,946,250 shares
of 123,180,519 outstanding shares and own 27.56% of the company stock.
Largest 10 shareholders include Broadfin Capital, LLC (7,350,000 shares), BAKER BROS. ADVISORS LP (5,102,153 shares), venBio Select Advisor LLC (3,804,745 shares), BlackRock Inc. (3,587,286 shares), VANGUARD GROUP INC (3,348,549 shares), JPMORGAN CHASE & CO (1,536,300 shares), STATE STREET CORP (938,195 shares), KENNEDY CAPITAL MANAGEMENT, INC. (918,438 shares), RENAISSANCE TECHNOLOGIES LLC (891,800 shares), and NORTHERN TRUST CORP (802,566 shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.